The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies

Research output: Contribution to journalReviewResearchpeer-review

Standard

The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. / Mølstrøm, Ida-Marie; Nordgaard, Julie ; Urfer Parnas, Annick; Handest, Rasmus; Berge, Jonas; Henriksen, Mads Gram.

In: Schizophrenia Research, Vol. 250, 2022, p. 152-163.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Mølstrøm, I-M, Nordgaard, J, Urfer Parnas, A, Handest, R, Berge, J & Henriksen, MG 2022, 'The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies', Schizophrenia Research, vol. 250, pp. 152-163. https://doi.org/10.1016/j.schres.2022.11.010

APA

Mølstrøm, I-M., Nordgaard, J., Urfer Parnas, A., Handest, R., Berge, J., & Henriksen, M. G. (2022). The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. Schizophrenia Research, 250, 152-163. https://doi.org/10.1016/j.schres.2022.11.010

Vancouver

Mølstrøm I-M, Nordgaard J, Urfer Parnas A, Handest R, Berge J, Henriksen MG. The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. Schizophrenia Research. 2022;250:152-163. https://doi.org/10.1016/j.schres.2022.11.010

Author

Mølstrøm, Ida-Marie ; Nordgaard, Julie ; Urfer Parnas, Annick ; Handest, Rasmus ; Berge, Jonas ; Henriksen, Mads Gram. / The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. In: Schizophrenia Research. 2022 ; Vol. 250. pp. 152-163.

Bibtex

@article{7d1ccdaf597d40ada89e0ad1b5770016,
title = "The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies",
abstract = "Objective: The aim was to examine the general outcome of schizophrenia after 20 years or more.Methods: Using the PRISMA guidelines, we conducted a systematic review and meta-analysis with metaregression on long-term follow-up studies of schizophrenia up until April 21, 2021. We included prospective studies with at least 20 years of follow-up on patients with a diagnosis of schizophrenia, and the studies had to include face-to-face clinical evaluation. We examined outcome in three nested groups: {\textquoteleft}recovery{\textquoteright}, {\textquoteleft}good or better{\textquoteright} (including also {\textquoteleft}recovery{\textquoteright}), and {\textquoteleft}moderate or better{\textquoteright} (including also {\textquoteleft}recovery{\textquoteright} and {\textquoteleft}good or better{\textquoteright}). We used random-effects meta-analysis and meta-regression to examine mean estimates and possible moderators.Results: We identified 1089 records, which were screened by two independent researchers. 14 prospective studies (1991 patients) published between 1978 and 2020 were found eligible. The studies used a range of different scales and definitions for outcome, and some used the same definitions for different outcomes. To compareoutcome across studies, we designed and applied a unified template for outcome definitions and cutoffs, based on earlier studies' recommendations. Our meta-analysis found that 24.2 % had {\textquoteleft}recovered{\textquoteright} (n = 246, CI: 20.3–28.0%), 35.5 % had a {\textquoteleft}good or better{\textquoteright} outcome (n = 766, CI: 26.0–45.0%), and 59.7% had {\textquoteleft}moderate or better{\textquoteright}outcome (n = 1139, CI: 49.3–70.1 %).Conclusions: The results contribute to debunk the myth that schizophrenia inevitably has a deteriorating course. Recovery is certainly possible. Schizophrenia remains, however, a severe and complex mental disorder, exhibiting a limited change in prognosis despite >100 years of research and efforts to improve treatment.",
author = "Ida-Marie M{\o}lstr{\o}m and Julie Nordgaard and {Urfer Parnas}, Annick and Rasmus Handest and Jonas Berge and Henriksen, {Mads Gram}",
year = "2022",
doi = "10.1016/j.schres.2022.11.010",
language = "English",
volume = "250",
pages = "152--163",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies

AU - Mølstrøm, Ida-Marie

AU - Nordgaard, Julie

AU - Urfer Parnas, Annick

AU - Handest, Rasmus

AU - Berge, Jonas

AU - Henriksen, Mads Gram

PY - 2022

Y1 - 2022

N2 - Objective: The aim was to examine the general outcome of schizophrenia after 20 years or more.Methods: Using the PRISMA guidelines, we conducted a systematic review and meta-analysis with metaregression on long-term follow-up studies of schizophrenia up until April 21, 2021. We included prospective studies with at least 20 years of follow-up on patients with a diagnosis of schizophrenia, and the studies had to include face-to-face clinical evaluation. We examined outcome in three nested groups: ‘recovery’, ‘good or better’ (including also ‘recovery’), and ‘moderate or better’ (including also ‘recovery’ and ‘good or better’). We used random-effects meta-analysis and meta-regression to examine mean estimates and possible moderators.Results: We identified 1089 records, which were screened by two independent researchers. 14 prospective studies (1991 patients) published between 1978 and 2020 were found eligible. The studies used a range of different scales and definitions for outcome, and some used the same definitions for different outcomes. To compareoutcome across studies, we designed and applied a unified template for outcome definitions and cutoffs, based on earlier studies' recommendations. Our meta-analysis found that 24.2 % had ‘recovered’ (n = 246, CI: 20.3–28.0%), 35.5 % had a ‘good or better’ outcome (n = 766, CI: 26.0–45.0%), and 59.7% had ‘moderate or better’outcome (n = 1139, CI: 49.3–70.1 %).Conclusions: The results contribute to debunk the myth that schizophrenia inevitably has a deteriorating course. Recovery is certainly possible. Schizophrenia remains, however, a severe and complex mental disorder, exhibiting a limited change in prognosis despite >100 years of research and efforts to improve treatment.

AB - Objective: The aim was to examine the general outcome of schizophrenia after 20 years or more.Methods: Using the PRISMA guidelines, we conducted a systematic review and meta-analysis with metaregression on long-term follow-up studies of schizophrenia up until April 21, 2021. We included prospective studies with at least 20 years of follow-up on patients with a diagnosis of schizophrenia, and the studies had to include face-to-face clinical evaluation. We examined outcome in three nested groups: ‘recovery’, ‘good or better’ (including also ‘recovery’), and ‘moderate or better’ (including also ‘recovery’ and ‘good or better’). We used random-effects meta-analysis and meta-regression to examine mean estimates and possible moderators.Results: We identified 1089 records, which were screened by two independent researchers. 14 prospective studies (1991 patients) published between 1978 and 2020 were found eligible. The studies used a range of different scales and definitions for outcome, and some used the same definitions for different outcomes. To compareoutcome across studies, we designed and applied a unified template for outcome definitions and cutoffs, based on earlier studies' recommendations. Our meta-analysis found that 24.2 % had ‘recovered’ (n = 246, CI: 20.3–28.0%), 35.5 % had a ‘good or better’ outcome (n = 766, CI: 26.0–45.0%), and 59.7% had ‘moderate or better’outcome (n = 1139, CI: 49.3–70.1 %).Conclusions: The results contribute to debunk the myth that schizophrenia inevitably has a deteriorating course. Recovery is certainly possible. Schizophrenia remains, however, a severe and complex mental disorder, exhibiting a limited change in prognosis despite >100 years of research and efforts to improve treatment.

U2 - 10.1016/j.schres.2022.11.010

DO - 10.1016/j.schres.2022.11.010

M3 - Review

C2 - 36417817

VL - 250

SP - 152

EP - 163

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -

ID: 324679717